HGHeather Woodworth Goff

Heather Woodworth Goff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heather Woodworth Goff has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to ‘Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides’

    by Victoria Garfinkel, Beth A Childs, Brielle E Johnson, Kiran A Kumar, Todd A Aguilera, Praveen R Geethakumari, Heather W Goff

    Authors’ response to ‘Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides’, by Oleg Akilov.

  • Open Access

    Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: a retrospective cohort study

    by Victoria Garfinkel, Beth A Childs, Brielle E Johnson, Kiran A Kumar, Todd A Aguilera, Praveen Ramakrishnan Geethakumari, Heather W Goff

    Dear Editor, Cutaneous T-cell lymphomas (CTCLs) are rare non-Hodgkin lymphomas, affecting 8.8 per 1 000 000 people annually.1 Bexarotene is the only retinoid approved by the US Food and Drug Administration for mycosis fungoides (MF),2 the most common CTCL subtype, but its use is limited by high cost and adverse effects, particularly thyroid and lipid abnormalities.3 Acitretin, a less expensive second-generation retinoid used in psoriasis, is prescribed off-label in MF, yet supporting data remain limited to small retrospective case series.4 However, our clinical experience suggests dose-dependent efficacy with acitretin, supporting formal evaluation of its dose–response pattern in MF.


  • Open Access

    Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

    by Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera

    Background: Sézary syndrome (SS) and leukaemic mycosis fungoides (MF) are aggressive cutaneous T‐cell lymphomas (CTCLs) with poor prognosis and limited treatment options. Single‐cell RNA sequencing (scRNA‐seq) offers an opportunity to dissect malignant heterogeneity and immune dysregulation yet has been underutilized in leukaemic CTCL. Objectives: To define transcriptional heterogeneity within malignant T cells, identify immunomodulatory signals shaping the tumour microenvironment and uncover actionable vulnerabilities in SS and leukaemic MF. Methods: We analysed 144,321 peripheral blood mononuclear cells from 22 patients (SS or leukaemic MF) and 7 healthy controls using scRNA‐seq, with CITE‐seq and TCR‐seq in subsets. Public and prospectively collected datasets were integrated after rigorous per‐sample quality control, batch correction and malignancy assignment. Differential gene expression and cell–cell communication analyses were performed using complementary modelling approaches with correction for sparsity and multiple testing. Results: Three transcriptionally distinct malignant T‐cell (MTC) subtypes were identified: central memory‐like (MTC CM), effector/effector memory‐like (MTC E/EM) and regulatory‐like (MTC Reg), each with unique expression programmes and putative vulnerabilities. MTC CM, the dominant population, expressed central memory markers, Th2/Th22 skewing and a broader KIR repertoire ( KIR3DL2, KIR3DL1, KIR2DL3 ) than previously reported. MTC E/EM and MTC Reg were enriched for NR4A1 and ITGB1 , respectively. Cell–cell communication analysis revealed KIR–MHC‐I signalling and suggested that MTC‐derived TNF and IL‐10 may drive JAK/STAT pathway activity in non‐T cells, indicating an underrecognized dimension of tumour‐induced immune reprogramming. Conclusions: This is one of the most comprehensive single‐cell studies of leukaemic CTCL to date. We uncover new malignant T‐cell states, broaden the known repertoire of KIR expression, and propose mechanisms of immune evasion that may contribute to treatment resistance. These findings lay the groundwork for subtype‐specific and microenvironment‐informed therapeutic strategies in Sézary syndrome, with potential implications for guiding targeted therapy selection but require validation in larger, independent cohorts.


  • Open Access

    Single-Cell Profiling Reveals Targetable Malignant T-Cell Subtypes and Immune Evasion Pathways in Sézary Syndrome

    by Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera

    Background: Sézary syndrome (SS) is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) with limited therapeutic options and a median survival of fewer than five years. Despite advances in how single-cell RNA sequencing (scRNA-seq) has improved the understanding and treatment of other cancer types, such insights in SS remain limited. The drivers of disease progression and immunologic dysfunction are incompletely defined, underscoring the need to characterize both malignant T cells (MTCs) and their interactions with surrounding immune populations. Objectives: To systematically characterize malignant and non-malignant immune cells in CTCL, identify distinct malignant T-cell subtypes, and uncover transcriptional programs and immune evasion pathways with therapeutic relevance. Methods: We analyzed scRNA-seq data on peripheral blood mononuclear cells (PBMCs) from 22 SS patients and 7 healthy controls. MTC subtypes were identified using a combination of transcriptional profiling, copy number variation (CNV) analysis, and T-cell receptor (TCR) clonotyping. CITE-seq was utilized on a subset of samples to correlate genetic findings with surface protein expression. Results: We identified three MTC subtypes: (1) MTC central memory (CM), a Th2-skewed CM phenotype that constituted the dominant malignant population; (2) MTC effector/effector-memory (E/EM), a subset enriched in Th1-associated genes; and (3) MTC regulatory (Reg), a regulatory-like, exhausted phenotype, along with shared and subtype-specific gene signatures. The predominance of MTC CM suggests a stable malignant state, while relative rarity of MTC E/EM and MTC Reg may reflect treatment effects or disease progression. In addition to KIR3DL2 , we identified KIR2DL3 and KIR3DL1 as upregulated immune-evasive receptors on MTCs and surrounding cells. Tensor factorization of ligand-receptor interactions revealed pro-inflammatory yet immunosuppressive signaling in myeloid cells converging on STAT3 activation. Conclusions: This study defines three transcriptionally and functionally distinct MTC subtypes in SS, highlighting subtype-specific vulnerabilities that may inform personalized treatment strategies. Our findings suggest that targeting not only MTCs but also KIR-family receptor signaling and JAK-STAT activation in the immune microenvironment may have therapeutic implications. The identification of novel immunosuppressive pathways and cell survival mechanisms opens avenues for tailored interventions – including widespread KIR inhibition, repurposing JAK inhibitors, and other novel therapies – to improve patient outcomes in SS. Contributor Statement: B.A. Childs conducted the conceptualization (equal), data curation (equal), formal analysis (lead), investigation (lead), methodology (equal), validation (equal), visualization (equal), writing – original draft (lead), writing – review & editing (supporting). E. Elghonaimy provided conceptualization (equal), data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), resources (equal), supervision (equal), validation (equal), visualization (equal), writing – original draft (supporting), and writing – review & editing (supporting). P. R. Geethakumari provided data curation (supporting), investigation (supporting), resources (supporting), writing – review & editing (supporting). K. Kumar contributed conceptualization (supporting), data curation (supporting), resources (supporting), and writing – review & editing (supporting). J. F. Merola provided conceptualization (supporting), investigation (supporting), resources (supporting), writing – review & editing (supporting). H.W. Goff contributed conceptualization (equal), data curation (equal), formal analysis (supporting), funding acquisition (lead), investigation (supporting), methodology (supporting), resources (supporting), supervision (equal), visualization (equal), writing – review & editing (equal). T. A. Aguilera provided conceptualization of the project (equal), data curation (equal), formal analysis (equal), funding acquisition (equal), investigation (equal), methodology (equal), project administration (equal), resources (lead), supervision (lead), visualization (supporting), writing – original draft (supporting), writing – review & editing (equal). T.A. Aguilera is the guarantor and accepts full responsibility for the overall content, had access to all the data, and controlled the decision to publish. Bulleted Statements: What is already known about this topic?: Sézary syndrome is a rare, aggressive CTCL subtype associated with poor survival; a minority of patients achieve long-term remission with allogeneic stem cell transplant. KIR3DL2 is an investigational target with ongoing trials (e.g., lacutamab, anti- KIR3DL2 agent). JAK inhibitors have shown mixed effects, with anecdotal benefit and potential harm. The heterogeneous biology of Sezary cells remains poorly characterized, limiting diagnostic and therapeutic advancement. What does this study add?: We define three distinct malignant T-cell subtypes in Sézary syndrome, each with clinical and therapeutic implications, and a unifying genetic signature. In addition to KIR3DL2 , a known CTCL marker, we identify KIR2DL3 and KIR3DL1 , inhibitory receptors implicated in viral and autoimmune regulation, as additional immune evasion mechanisms. JAK/STAT activation in neighboring myeloid cells may be driven by Sezary cell signaling through S100A8 , S100A9 , CD74 , IL-10 , and TNF , a potentially targetable axis. What is the translational message?: The predominance of a central memory–like malignant phenotype, alongside other distinct subsets reveal an opportunity for subtype-guided treatment strategies. Optimal therapeutic targeting may include both malignant T cells and interacting immune cells. Our findings identify targets that may be actionable, including KIR-family receptors and STAT3-related signaling. Insights from other T-cell disorders may guide repurposing of existing therapies to improve outcomes. Lay Summary: How Sezay Syndrome, a Type of Skin Lymphoma, Impacts the Immune System: Sézary syndrome (SS) is a rare and aggressive form of skin cancer that starts in the blood. It is a type of cutaneous T-cell lymphoma (CTCL), where cancerous T cells (a kind of white blood cell) spread from the bloodstream to the skin. SS mainly affects adults and has limited treatment options, with most people living less than five years after diagnosis. This study, based in the United States, aimed to understand how cancerous T cells behave in SS and how they interact with other immune cells. We used a method called single-cell RNA sequencing to examine over 100,000 individual immune cells from the blood of 22 patients with SS and 7 healthy individuals. This allowed us to see which genes were active in each cell. We found that the cancerous T cells in SS are not all the same. Instead, they fall into three distinct groups: one resembled central memory T cells that typically live in the blood, one looked more aggressive and inflammatory, and one resembled exhausted regulatory immune cells. We also discovered that cancer cells and surrounding immune cells expressed molecules called KIRs, which may help them avoid being attacked. Other immune cells released signals that turned on a pathway called JAK-STAT, which may further protect the cancer. These findings reveal new ways that SS protects itself and avoids the immune system. Understanding these escape routes may help guide future treatments, including drug combinations that block these signals and improve patient outcomes. Abbreviated Single-cell RNA and protein profiling of Sézary syndrome reveals three distinct malignant T-cell subtypes and uncovers convergent immunosuppressive signaling through KIR-family receptors and STAT3 activation. These findings expose targetable pathways driving immune evasion and offer a foundation for more personalized therapeutic strategies in this aggressive form of cutaneous T-cell lymphoma.

  • Radiofrequency Microneedling in Treating Primary Hyperhidrosis: A Systematic Review and Meta-Analysis

    by Mayuri H. Ba Vaish, Edward Hadeler, Anisha Guda, Heather Goff

    BACKGROUND: Radiofrequency microneedling (RFM) is a potential treatment for primary hyperhidrosis. However, its efficacy is unclear, and treatment parameters and outcomes vary across studies. OBJECTIVE: To understand the effect of RFM on treating primary hyperhidrosis, as measured by changes in the Hyperhidrosis Disease Severity Score (HDSS) before and after treatment, and to clearly define treatment settings most likely to optimize results. MATERIALS AND METHODS: A systematic literature search utilizing Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was conducted across PubMed, EMBASE, MEDLINE, Web of Science, and the Cochrane Library. Studies were evaluated for risk of bias via the ROBINS-I tool and Levels of Evidence/GRADE criteria. A random forest model identified RFM settings that predict HDSS score decrease. RESULTS: Six publications met inclusion criteria. The level of evidence was classified as Grade B, indicating moderate quality. RFM intervention resulted in a mean HDSS score decrease of 1.63 (52% reduction, p < .05). The strongest predictors for HDSS score decrease were dwell time, energy, and depth, with feature importances of 0.43, 0.19, and 0.15 respectively. CONCLUSION: Radiofrequency microneedling treatment significantly reduces HDSS scores in patients with primary hyperhidrosis. Moving forward, it would benefit physicians to standardize objective protocols in reporting RFM parameters and measuring outcomes.


  • Cutaneous malignancy in chronic lymphocytic leukemia: A global, active comparator retrospective cohort study

    by Kyle C. Lauck, Rajiv I. Nijhawan, Stanislav N. Tolkachjov, Heather W. Goff

  • Open Access

    A Retrospective Comparison Between Home and in‐Office NB‐UVB Efficacy for Patients With Mycosis Fungoides

    by Victoria Garfinkel, Joan S. Reisch, Heather Woodworth Goff

    Introduction: This study addresses the gap in research comparing the effectiveness between home and in‐office narrowband ultraviolet B (NB‐UVB) phototherapy for the treatment of mycosis fungoides (MF). Elderly and disabled patients with this condition disproportionally lack access to home units due to insurance denial.Materials and Methods: A retrospective review included patients diagnosed with MF or Sezary syndrome who underwent either in‐office or home UVB between 2016 and 2023. Eighty‐four patients used home NB‐UVB, while 75 used in‐office. Clinical characteristics, treatment response, and access were evaluated.Results: Overall, there was no significant difference in response rates between home and in‐office NB‐UVB phototherapy. Subgroup analysis based on adjuvant treatment revealed a significant difference in clinical response rates for patients using NB‐UVB with topicals (p = 0.008) and NB‐UVB with multiple systemic therapies (p = 0.04). Financial and time constraints were the most common cause of treatment discontinuation for in‐office patients (28%).Conclusions: The effectiveness of home NB‐UVB treatment is comparable, if not superior, to in‐office treatment, likely attributed to treatment ease in access and compliance. Medicare and other health insurance companies should expand coverage to include home‐based phototherapy for patients with MF, a potentially fatal cancer with a relative paucity of effective alternate therapies.


  • Open Access

    Hyper-dilute botulinum toxin as an effective treatment for refractory erythromelalgia

    by Ariel Brown, Duaa AbdelHameid, Kaveh Nezafati, Heather W. Goff


  • Whole-Exome Sequencing Identifies Novel and Previously Reported Mutations in a Case of Intravascular B-Cell Lymphoma

    by Beth A. Childs, Jiwoong Kim, Ravi R. Patel, Travis W. Vandergriff, Heather W. Goff, Richard C. Wang